These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29101681)

  • 1. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
    Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
    Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment.
    Turk D; Boeri M; Abraham L; Atkinson J; Bushmakin AG; Cappelleri JC; Hauber B; Klein K; Russo L; Viktrup L; Walsh D
    Osteoarthritis Cartilage; 2020 Sep; 28(9):1202-1213. PubMed ID: 32652238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
    Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
    J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
    Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
    Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
    Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey.
    Liu S; Liu J; Si L; Ke X; Liu L; Ren Y; Bao S; Li F; Yu Y; Pan Q; Wei Y; Chen Y
    BMJ Glob Health; 2023 Apr; 8(4):. PubMed ID: 37041021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
    Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
    Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
    Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
    Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
    Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.
    Hauber AB; Han S; Yang JC; Gantz I; Tunceli K; Gonzalez JM; Brodovicz K; Alexander CM; Davies M; Iglay K; Zhang Q; Radican L
    Patient Prefer Adherence; 2013; 7():937-49. PubMed ID: 24086104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
    Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
    Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferences for Patients with Type 2 Diabetes Mellitus for Medications in Shandong Province, China: A Discrete Choice Experiment.
    Lv Y; Ren R; Tang C; Song K; Li S; Wang H
    Patient Prefer Adherence; 2022; 16():2335-2344. PubMed ID: 36046499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
    de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
    Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.